Long‐term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia

ConclusionsAlthough results are not in favor of an effect of epoetin alfa in Friedreich ataxia, this is the largest trial testing its effect. It is still possible that epoetin alfa may show some symptomatic effect on upper‐limb performance. This study provides class I evidence that erythropoietin does not ameliorate VO2 max in patients with Friedreich ataxia. © 2016 International Parkinson and Movement Disorder Society

Source: Movement Disorders - February 16, 2016 Category: Neurology Authors: Francesco Saccà, Giorgia Puorro, Angela Marsili, Antonella Antenora, Chiara Pane, Carlo Casali, Christian Marcotulli, Giovanni Defazio, Daniele Liuzzi, Chiara Tatillo, Donata Maria Cambriglia, Giuseppe Schiano di Cola, Luigi Giuliani, Vincenzo Guardasole Tags: Research Article Source Type: research